Genmab A/S

Genmab develops antibody therapeutics for cancer and other diseases primarily in Denmark. The company markets DARZALEX for multiple myeloma and thyroid eye disease, as well as Amivantamab for gastric and esophageal cancer. Its products include treatments for blood cancers, AL amyloidosis, and solid tumors. The company also develops various antibodies for hematological malignancies and other diseases. Genmab has collaborations with Seagen, argenx, AbbVie, BioNTech, Janssen, and Novo Nordisk A/S. It operates pre-clinical programs and has a commercial license agreement with Seagen. The company was founded in 1999 and is headquartered in Copenhagen, Denmark.

Overview

Sector

Biotechnology

Target Price

455.0 DKK

Current Price

1507.5 DKK

Potential

-70%

Strengths

The company has low debt. Net Debt to EBITDA Ratio is -1.05 and it is lower than the sector mean.
The company has high returns. ROIC (20.60%) is higher than the sector mean (6.02%).
Strong EBITDA Margin of 40.97%.

Weaknesses

With a depreciation Potential of -68.81%, based on our fundamental analysis, it suggests the stock may be overvalued.

Key Financial Data

Indicator	Value
PER	87.5
EV/EBITDA	80.6
Price/Free Cash Flow'	91.9
ROIC	20.6%
Net Debt/EBITDA	-1.0